在固体瘤中应用CAR-T细胞治疗的困境和可能的解决方案
Lihong Wang1, Lufang Zhang2, Louisa Chard Dunmall3
1Department of Oncology, Air Force Medical Center, PLA, Beijing, China; National Centre for International Research in Cell and Gene Therapy, Sino British Research Centre for Molecular Oncology, State Key Laboratory of Esophageal Cancer Prevention & Treatment, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China.
化学抗原受体T (CAR-T) 细胞疗法对血液癌症有希望,但在固体瘤中面临挑战. 本综述探讨了克服固体瘤微环境的局限性,以实现CAR-T细胞治疗的成功.
科学领域:
- 免疫治疗是一种免疫疗法.
- 在瘤学瘤学.
- 细胞疗法细胞疗法
背景情况:
- 化学抗原受体T (CAR-T) 细胞疗法是对恶性瘤采用免疫疗法的重大进展.
- 卡-T细胞作为"活体药物",提供直接向瘤和长期免疫记忆.
- CD19.CAR-T细胞在血液性恶性瘤中表现出高疗效,在急性淋巴细胞白血病中>90%的反应,在非霍奇金淋巴瘤中>60%.
研究的目的:
- 在固体瘤微环境的背景下,审查CAR-T细胞治疗的局限性.
- 讨论新出现的解决方案和战略,以克服这些局限性.
- 预测CAR-T细胞治疗固体瘤的未来潜力.
主要方法:
- 对当前CAR-T细胞治疗应用和挑战的文献综述.
- 分析固体瘤微环境对CAR-T细胞疗效的影响.
- 综合了关于新型CAR-T细胞工程和治疗策略的最新研究.
主要成果:
- 在固体瘤中,CAR-T细胞疗法表现出有限的应答率和严重的副作用.
- 固体瘤的微环境对CAR-T细胞的功能构成了重要的生物学障碍.
- 目前正在开发各种策略,以增强固体瘤内的CAR-T细胞持久性和活性.
结论:
- 克服固体瘤微环境对于推进CAR-T细胞疗法至关重要.
- 未来的研究重点是设计CAR-T细胞以抵抗免疫抑制并改善瘤透.
- 目标是在固体瘤中实现CAR-T细胞治疗的可比成功率,如目前在血液瘤中所见.
更多相关视频
08:46A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
相关概念视频
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
